{
    "xml": "<topic id=\"PHP1369\" outputclass=\"drug\" rev=\"1.18\" type=\"drug\" namespace=\"/drugs/nimodipine\" basename=\"nimodipine\" title=\"NIMODIPINE\">\n<title>NIMODIPINE</title>\n<body>\r\n<p outputclass=\"interactionsLinks\"> List of individual interactants: <xref format=\"dita\" href=\"#bnf_int_476\" namespace=\"/interactions/list-of-drug-interactions/calcium-channel-blockers/calcium-channel-blockers-dihydropyridines/nimodipine\">Nimodipine</xref>\n</p>\n<data name=\"vtmid\">87285001</data>\n<data name=\"classifications\">\n<data name=\"classification\">\n<data name=\"drugClassification\">\n<xref format=\"dita\" scope=\"local\" type=\"drugClassification\" href=\"#_762273848\" title=\"Calcium-channel blockers\">Calcium-channel blockers</xref>\n</data>\n<data name=\"inheritsFromClass\">\n<xref format=\"dita\" scope=\"local\" type=\"drugClass\" href=\"#PHP34525\" title=\"CALCIUM-CHANNEL BLOCKERS\" namespace=\"/drug-classes/calcium-channel-blockers\">CALCIUM-CHANNEL BLOCKERS</xref>\n</data>\n</data>\n</data>\n<data name=\"primaryDomainOfEffect\">\n<data name=\"domainOfEffect\">  </data>\n</data>\r\n</body>\n<topic id=\"PHP71803\" outputclass=\"drugAction\" rev=\"1.7\" parent=\"/drugs/nimodipine\">\n<title>Drug action</title>\n<body>\n<section>\n<sectiondiv>\n<p>Nimodipine is a dihydropyridine calcium-channel blocker.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP71737\" outputclass=\"indicationsAndDose\" rev=\"1.50\" parent=\"/drugs/nimodipine\">\n<title>Indications and dose</title>\n<body>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Prevention of ischaemic neurological defects following aneurysmal subarachnoid haemorrhage</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By mouth</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>60&#8239;mg every 4&#8239;hours, to be started within 4 days of aneurysmal subarachnoid haemorrhage and continued for 21 days.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Treatment of ischaemic neurological defects following aneurysmal subarachnoid haemorrhage</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By intravenous infusion</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult (body-weight up to 70 kg)</p>\n<p>Initially 0.5&#8239;mg/hour, increased after 2 hours if no severe fall in blood pressure; increased to 2&#8239;mg/hour and continue for at least 5 days (max. 14 days); if surgical intervention during treatment, continue for at least 5 days after surgery; max. total duration of nimodipine use 21 days, to be given via central catheter.</p>\n</li>\n<li outputclass=\"patientGroup adult\">\n<p>Adult (body-weight 70 kg and above)</p>\n<p>Initially 1&#8239;mg/hour, increased after 2 hours if no severe fall in blood pressure; increased to 2&#8239;mg/hour and continue for at least 5 days (max. 14 days); if surgical intervention during treatment, continue for at least 5 days after surgery; max. total duration of nimodipine use 21 days, to be given via central catheter.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Treatment of ischaemic neurological defects following aneurysmal subarachnoid haemorrhage in patients with unstable blood pressure</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By intravenous infusion</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>Initially up to 0.5&#8239;mg/hour, increased after 2 hours if no severe fall in blood pressure; increased to 2&#8239;mg/hour and continue for at least 5 days (max. 14 days); if surgical intervention during treatment, continue for at least 5 days after surgery; max. total duration of nimodipine use 21 days, to be given via central catheter.</p>\n</li>\n</ul>\n</section>\n</body>\n</topic>\n<topic id=\"PHP71817\" outputclass=\"contraindications\" rev=\"1.14\" parent=\"/drugs/nimodipine\">\n<title>Contra-indications</title>\n<body>\r\n<section outputclass=\"contraindications\">\r\n<p>\r\n<ph outputclass=\"contraindication\">\r\n<xref format=\"dita\" href=\"#PHP78608\" type=\"bookmark\" namespace=\"/treatment-summaries/acute-porphyrias\">Acute porphyrias</xref>\r\n</ph>; <ph outputclass=\"contraindication\">unstable angina</ph>; <ph outputclass=\"contraindication\">within 1 month of myocardial infarction</ph>\r\n</p>\r\n </section>\r\n\r\n\r\n\r\n\r\n\r\n\r\n</body>\n</topic>\n<topic id=\"PHP71830\" outputclass=\"cautions\" rev=\"1.7\" parent=\"/drugs/nimodipine\">\n<title>Cautions</title>\n<body>\n<section outputclass=\"cautions\">\n<p>\n<ph outputclass=\"caution\">Cerebral oedema</ph>; <ph outputclass=\"caution\">hypotension</ph>; <ph outputclass=\"caution\">severely raised intracranial pressure</ph>\n</p>\n</section>\n</body>\n</topic>\n<topic id=\"PHP71730\" outputclass=\"interactions\" rev=\"1.13\" parent=\"/drugs/nimodipine\">\n<title>Interactions</title>\n<body>\n<section outputclass=\"general\">\n<sectiondiv>\n<p>Appendix 1 (calcium-channel blockers, alcohol (infusion only)).</p>\n<p>Avoid concomitant administration with other calcium-channel blockers, beta-blocker and nephrotoxic drugs.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP71703\" outputclass=\"sideEffects\" rev=\"1.15\" parent=\"/drugs/nimodipine\">\n<title>Side-effects</title>\n<body>\n<section outputclass=\"generalSideEffects\">\n<sectiondiv outputclass=\"frequencies\">\n<sectiondiv outputclass=\"notKnown\">\n<p outputclass=\"title\">Frequency not known</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Flushing</ph>; <ph outputclass=\"sideEffect\">gastro-intestinal disorders</ph>; <ph outputclass=\"sideEffect\">headache</ph>; <ph outputclass=\"sideEffect\">hypotension</ph>; <ph outputclass=\"sideEffect\">ileus</ph>; <ph outputclass=\"sideEffect\">nausea</ph>; <ph outputclass=\"sideEffect\">sweating and feeling of warmth</ph>; <ph outputclass=\"sideEffect\">thrombocytopenia</ph>; <ph outputclass=\"sideEffect\">variation in heart-rate</ph>\n</p>\n</sectiondiv>\n</sectiondiv>\n</section>\n<section outputclass=\"sideEffectsOverdosageInformation\">\n<title>Overdose</title>\n<sectiondiv>\n<p>In overdose, the dihydropyridine calcium-channel blockers cause severe hypotension secondary to profound peripheral vasodilatation</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP71726\" outputclass=\"pregnancy\" parent=\"/drugs/nimodipine\">\n<title>Pregnancy</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Manufacturer advises use only if potential benefit outweighs risk.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP71839\" outputclass=\"breastFeeding\" parent=\"/drugs/nimodipine\">\n<title>Breast feeding</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Manufacturer advises avoid&#8212;present in milk.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP71847\" outputclass=\"directionsForAdministration\" rev=\"1.13\" parent=\"/drugs/nimodipine\">\n<title>Directions for administration</title>\n<body>\n<section>\n<sectiondiv>\n<p outputclass=\"specificity\">With <ph outputclass=\"route\">oral</ph> use</p>\n<p>For administration <i>by mouth</i>, tablets may be crushed or halved but are light sensitive&#8212;administer immediately.</p>\n</sectiondiv>\n<sectiondiv>\n<p outputclass=\"specificity\">With <ph outputclass=\"route\">intravenous</ph> use</p>\n<p>For <i>intravenous infusion</i>, give <i>via</i> drip tubing in Glucose 5% or Sodium chloride 0.9%. Not to be added to infusion container; administer via an infusion pump through a Y-piece into a central catheter; incompatible with polyvinyl chloride giving sets or containers; protect infusion from light.</p>\n</sectiondiv>\n<sectiondiv>\n<p>Avoid concomitant administration of nimodipine infusion and tablets.</p>\n</sectiondiv>\n<sectiondiv>\n<p outputclass=\"specificity\">With <ph outputclass=\"route\">intravenous</ph> use</p>\n<p>Polyethylene, polypropylene, or glass apparatus should be used.</p>\n<p>PVC should be avoided.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP1369-medicinalForms\" outputclass=\"medicinalForms\" parent=\"/drugs/nimodipine\">\n<title>Medicinal forms</title>\n<body>\n<section outputclass=\"licensingVariationStatement\">\n<p>There can be variation in the licensing of different medicines containing the same drug.</p>\n</section>\n<p>Forms available from special-order manufacturers include: oral suspension</p>\n</body>\n</topic>\n<parents>\n<xref format=\"dita\" scope=\"local\" type=\"drugs\" href=\"#drugs\" title=\"Drugs\" namespace=\"/drugs\">Drugs</xref>\n</parents>\n<children>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP74855\" title=\"Tablet\" namespace=\"/drugs/nimodipine/tablet\">Tablet</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP74862\" title=\"Solution for infusion\" namespace=\"/drugs/nimodipine/solution-for-infusion\">Solution for infusion</xref>\n</children>\n<backlinks>\n<xref format=\"dita\" scope=\"local\" type=\"drugClassifications\" href=\"#PHP106980\" namespace=\"/drug-classifications\" title=\"Drug classifications\" count=\"1\" rel=\"backlink\">Drug classifications</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP78483\" namespace=\"/treatment-summaries/calcium-channel-blockers\" title=\"Calcium-channel blockers\" count=\"2\" rel=\"backlink\">Calcium-channel blockers</xref>\n</backlinks>\n<links>\n<xref format=\"dita\" scope=\"local\" type=\"interaction\" href=\"#bnf_int_476\" namespace=\"/interactions/list-of-drug-interactions/calcium-channel-blockers/calcium-channel-blockers-dihydropyridines/nimodipine\" title=\"Nimodipine\" count=\"1\" rel=\"link\">Nimodipine</xref>\n<xref format=\"dita\" scope=\"local\" type=\"drugClass\" href=\"#PHP34525\" namespace=\"/drug-classes/calcium-channel-blockers\" title=\"CALCIUM-CHANNEL BLOCKERS\" count=\"1\" rel=\"link\">CALCIUM-CHANNEL BLOCKERS</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP78608\" namespace=\"/treatment-summaries/acute-porphyrias\" title=\"Acute porphyrias\" count=\"1\" rel=\"link\">Acute porphyrias</xref>\n<xref format=\"dita\" scope=\"local\" type=\"#drugs\" href=\"#drugs\" namespace=\"/drugs\" title=\"Drugs\" count=\"1\" rel=\"link\">Drugs</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP74855\" namespace=\"/drugs/nimodipine/tablet\" title=\"Tablet\" count=\"1\" rel=\"link\">Tablet</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP74862\" namespace=\"/drugs/nimodipine/solution-for-infusion\" title=\"Solution for infusion\" count=\"1\" rel=\"link\">Solution for infusion</xref>\n</links>\n</topic>",
    "id": "PHP1369",
    "outputclass": "drug",
    "rev": "1.18",
    "type": "drug",
    "namespace": "/drugs/nimodipine",
    "basename": "nimodipine",
    "title": "NIMODIPINE",
    "interactants": [
        {
            "id": "bnf_int_476",
            "label": "Nimodipine"
        }
    ],
    "vtmid": "87285001",
    "drugClassification": [
        "Calcium-channel blockers"
    ],
    "inheritsFromClass": [
        "CALCIUM-CHANNEL BLOCKERS"
    ],
    "primaryDomainOfEffect": {
        "": {
            "domain": "",
            "therapeuticUses": {}
        }
    },
    "drugAction": {
        "drugAction": [
            {
                "type": "drugAction",
                "textContent": "Nimodipine is a dihydropyridine calcium-channel blocker.",
                "html": "<p>Nimodipine is a dihydropyridine calcium-channel blocker.</p>"
            }
        ]
    },
    "indicationsAndDoses": {
        "indicationAndDoseGroups": [
            {
                "indications": [
                    {
                        "textContent": "Prevention of ischaemic neurological defects following aneurysmal subarachnoid haemorrhage",
                        "html": "Prevention of ischaemic neurological defects following aneurysmal subarachnoid haemorrhage"
                    }
                ],
                "specificity": {
                    "routes": [
                        "mouth"
                    ],
                    "textContent": "By mouth",
                    "html": "By mouth"
                },
                "adult": [
                    {
                        "textContent": "60 mg every 4 hours, to be started within 4 days of aneurysmal subarachnoid haemorrhage and continued for 21 days.",
                        "html": "<p>60&#8239;mg every 4&#8239;hours, to be started within 4 days of aneurysmal subarachnoid haemorrhage and continued for 21 days.</p>"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Treatment of ischaemic neurological defects following aneurysmal subarachnoid haemorrhage",
                        "html": "Treatment of ischaemic neurological defects following aneurysmal subarachnoid haemorrhage"
                    }
                ],
                "specificity": {
                    "routes": [
                        "intravenous infusion"
                    ],
                    "textContent": "By intravenous infusion",
                    "html": "By intravenous infusion"
                },
                "adult": [
                    {
                        "textContent": "Initially 0.5 mg/hour, increased after 2 hours if no severe fall in blood pressure; increased to 2 mg/hour and continue for at least 5 days (max. 14 days); if surgical intervention during treatment, continue for at least 5 days after surgery; max. total duration of nimodipine use 21 days, to be given via central catheter.",
                        "html": "<p>Initially 0.5&#8239;mg/hour, increased after 2 hours if no severe fall in blood pressure; increased to 2&#8239;mg/hour and continue for at least 5 days (max. 14 days); if surgical intervention during treatment, continue for at least 5 days after surgery; max. total duration of nimodipine use 21 days, to be given via central catheter.</p>",
                        "ageGroup": "(body-weight up to 70 kg)"
                    },
                    {
                        "textContent": "Initially 1 mg/hour, increased after 2 hours if no severe fall in blood pressure; increased to 2 mg/hour and continue for at least 5 days (max. 14 days); if surgical intervention during treatment, continue for at least 5 days after surgery; max. total duration of nimodipine use 21 days, to be given via central catheter.",
                        "html": "<p>Initially 1&#8239;mg/hour, increased after 2 hours if no severe fall in blood pressure; increased to 2&#8239;mg/hour and continue for at least 5 days (max. 14 days); if surgical intervention during treatment, continue for at least 5 days after surgery; max. total duration of nimodipine use 21 days, to be given via central catheter.</p>",
                        "ageGroup": "(body-weight 70 kg and above)"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Treatment of ischaemic neurological defects following aneurysmal subarachnoid haemorrhage in patients with unstable blood pressure",
                        "html": "Treatment of ischaemic neurological defects following aneurysmal subarachnoid haemorrhage in patients with unstable blood pressure"
                    }
                ],
                "specificity": {
                    "routes": [
                        "intravenous infusion"
                    ],
                    "textContent": "By intravenous infusion",
                    "html": "By intravenous infusion"
                },
                "adult": [
                    {
                        "textContent": "Initially up to 0.5 mg/hour, increased after 2 hours if no severe fall in blood pressure; increased to 2 mg/hour and continue for at least 5 days (max. 14 days); if surgical intervention during treatment, continue for at least 5 days after surgery; max. total duration of nimodipine use 21 days, to be given via central catheter.",
                        "html": "<p>Initially up to 0.5&#8239;mg/hour, increased after 2 hours if no severe fall in blood pressure; increased to 2&#8239;mg/hour and continue for at least 5 days (max. 14 days); if surgical intervention during treatment, continue for at least 5 days after surgery; max. total duration of nimodipine use 21 days, to be given via central catheter.</p>"
                    }
                ]
            }
        ]
    },
    "contraindications": {
        "contraindications": [
            {
                "type": "contraindications",
                "textContent": "Acute porphyrias",
                "html": "<xref format=\"dita\" href=\"#PHP78608\" type=\"bookmark\" namespace=\"/treatment-summaries/acute-porphyrias\">Acute porphyrias</xref>",
                "references": [
                    {
                        "id": "PHP78608",
                        "label": "Acute porphyrias"
                    }
                ]
            },
            {
                "type": "contraindications",
                "textContent": "unstable angina",
                "html": "unstable angina"
            },
            {
                "type": "contraindications",
                "textContent": "within 1 month of myocardial infarction",
                "html": "within 1 month of myocardial infarction"
            }
        ]
    },
    "cautions": {
        "cautions": [
            {
                "type": "cautions",
                "textContent": "Cerebral oedema",
                "html": "Cerebral oedema"
            },
            {
                "type": "cautions",
                "textContent": "hypotension",
                "html": "hypotension"
            },
            {
                "type": "cautions",
                "textContent": "severely raised intracranial pressure",
                "html": "severely raised intracranial pressure"
            }
        ]
    },
    "interactions": {
        "general": [
            {
                "type": "general",
                "textContent": "Appendix 1 (calcium-channel blockers, alcohol (infusion only)).\n\nAvoid concomitant administration with other calcium-channel blockers, beta-blocker and nephrotoxic drugs.",
                "html": "<p>Appendix 1 (calcium-channel blockers, alcohol (infusion only)).</p><p>Avoid concomitant administration with other calcium-channel blockers, beta-blocker and nephrotoxic drugs.</p>"
            }
        ]
    },
    "sideEffects": {
        "general": {
            "frequencies": {
                "notKnown": [
                    {
                        "type": "notKnown",
                        "textContent": "Flushing",
                        "html": "Flushing",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "gastro-intestinal disorders",
                        "html": "gastro-intestinal disorders",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "headache",
                        "html": "headache",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "hypotension",
                        "html": "hypotension",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "ileus",
                        "html": "ileus",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "nausea",
                        "html": "nausea",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "sweating and feeling of warmth",
                        "html": "sweating and feeling of warmth",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "thrombocytopenia",
                        "html": "thrombocytopenia",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "variation in heart-rate",
                        "html": "variation in heart-rate",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    }
                ]
            }
        },
        "overdosageInformation": [
            {
                "type": "overdosageInformation",
                "textContent": "In overdose, the dihydropyridine calcium-channel blockers cause severe hypotension secondary to profound peripheral vasodilatation",
                "html": "<p>In overdose, the dihydropyridine calcium-channel blockers cause severe hypotension secondary to profound peripheral vasodilatation</p>"
            }
        ]
    },
    "pregnancy": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Manufacturer advises use only if potential benefit outweighs risk.",
                "html": "<p>Manufacturer advises use only if potential benefit outweighs risk.</p>"
            }
        ]
    },
    "breastFeeding": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Manufacturer advises avoid&#8212;present in milk.",
                "html": "<p>Manufacturer advises avoid&#8212;present in milk.</p>"
            }
        ]
    },
    "directionsForAdministration": {
        "directionsForAdministration": [
            {
                "type": "directionsForAdministration",
                "specificity": {
                    "textContent": "With oral use",
                    "html": "With <ph outputclass=\"route\">oral</ph> use",
                    "routes": [
                        "oral"
                    ]
                },
                "textContent": "For administration by mouth, tablets may be crushed or halved but are light sensitive&#8212;administer immediately.",
                "html": "<p>For administration <i>by mouth</i>, tablets may be crushed or halved but are light sensitive&#8212;administer immediately.</p>"
            },
            {
                "type": "directionsForAdministration",
                "specificity": {
                    "textContent": "With intravenous use",
                    "html": "With <ph outputclass=\"route\">intravenous</ph> use",
                    "routes": [
                        "intravenous"
                    ]
                },
                "textContent": "For intravenous infusion, give via drip tubing in Glucose 5% or Sodium chloride 0.9%. Not to be added to infusion container; administer via an infusion pump through a Y-piece into a central catheter; incompatible with polyvinyl chloride giving sets or containers; protect infusion from light.",
                "html": "<p>For <i>intravenous infusion</i>, give <i>via</i> drip tubing in Glucose 5% or Sodium chloride 0.9%. Not to be added to infusion container; administer via an infusion pump through a Y-piece into a central catheter; incompatible with polyvinyl chloride giving sets or containers; protect infusion from light.</p>"
            },
            {
                "type": "directionsForAdministration",
                "textContent": "Avoid concomitant administration of nimodipine infusion and tablets.",
                "html": "<p>Avoid concomitant administration of nimodipine infusion and tablets.</p>"
            },
            {
                "type": "directionsForAdministration",
                "specificity": {
                    "textContent": "With intravenous use",
                    "html": "With <ph outputclass=\"route\">intravenous</ph> use",
                    "routes": [
                        "intravenous"
                    ]
                },
                "textContent": "Polyethylene, polypropylene, or glass apparatus should be used.\n\nPVC should be avoided.",
                "html": "<p>Polyethylene, polypropylene, or glass apparatus should be used.</p><p>PVC should be avoided.</p>"
            }
        ]
    },
    "medicinalForms": {
        "licensingVariationStatement": [
            {
                "type": "licensingVariationStatement",
                "textContent": "There can be variation in the licensing of different medicines containing the same drug.",
                "html": "<p>There can be variation in the licensing of different medicines containing the same drug.</p>"
            }
        ],
        "availableForms": {
            "before": "Forms available from special-order manufacturers include",
            "forms": [
                "oral suspension"
            ]
        }
    },
    "children": {
        "medicinalForm": [
            {
                "id": "PHP74855",
                "label": "Tablet",
                "type": "medicinalForm"
            },
            {
                "id": "PHP74862",
                "label": "Solution for infusion",
                "type": "medicinalForm"
            }
        ]
    },
    "backlinks": {
        "drugClassifications": [
            {
                "id": "PHP106980",
                "label": "Drug classifications",
                "type": "drugClassifications"
            }
        ],
        "treatmentSummary": [
            {
                "id": "PHP78483",
                "label": "Calcium-channel blockers",
                "type": "treatmentSummary"
            }
        ]
    },
    "links": {
        "interaction": [
            {
                "id": "bnf_int_476",
                "label": "Nimodipine",
                "type": "interaction"
            }
        ],
        "drugClass": [
            {
                "id": "PHP34525",
                "label": "CALCIUM-CHANNEL BLOCKERS",
                "type": "drugClass"
            }
        ],
        "treatmentSummary": [
            {
                "id": "PHP78608",
                "label": "Acute porphyrias",
                "type": "treatmentSummary"
            }
        ],
        "#drugs": [
            {
                "id": "drugs",
                "label": "Drugs",
                "type": "#drugs"
            }
        ],
        "medicinalForm": [
            {
                "id": "PHP74855",
                "label": "Tablet",
                "type": "medicinalForm"
            },
            {
                "id": "PHP74862",
                "label": "Solution for infusion",
                "type": "medicinalForm"
            }
        ]
    }
}